HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: Results of a double-blind, adjuvant-controlled, dose-ranging trial

AIDS

Volumn 8, Issue 10, 1994, Pages 1429-1435

  Turner, John L ^a   Trauger, Richard J ^b   Daigle, Anne E ^b   Carlo, Dennis J ^b  

^a GRADUATE HOSPITAL   (United States)

^b Orchestra Therapeutics Inc   (United States)

Author keywords

HIV 1 immunotherapy; HIV 1 specific delayed type hypersensitivity

Indexed keywords

ANTIGEN P24; FREUND ADJUVANT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ADULT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TEST; VIRUS IMMUNITY;

EID: 0027932801     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199410000-00009     Document Type: Article

References (19)

1. Wahren B, Morfeldt Mansson L, Biberfeld L, et al.: Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987, 61:2017-2023.
2. Giorgi JV, Fahey J, Smith DC, et al.: Early effects of HIV on CD4 lymphocytes in vivo. J Immunol 1987, 138:3725-3730.
3. Zeballos RS, Cavalcante N, Freire CA, et al.: Delayed hypersensitivity skin tests in prognosis of human immunodeficiency virus infection. J Clin Lab Anal 1992, 6:119-122.
4. Ballet JJ, Couderc LJ, Rabian Herzog C, et al.: Impaired T-lymphocyte-dependent immune responses to microbial antigens in patients with HIV-1-associated persistent generalized lymphadenopathy. AIDS 1988, 2:291-297.
5. Blatt SP, Hendrix CW, Butzin CA, et al.: Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med 1993, 119:177-184.
6. Birx DL, Brundage J, Larson K, et al.: The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. J Acquir Immune Defic Syndr 1993, 6:1248-1257.
7. Salk J: Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987, 327:4736.
8. Gibbs CJ Jr, Peters R, Gravell M, et al.: Observations following HIV immunization and challenge of HIV seropositive and seronegative chimpanzees. Proc Natl Acad Sci USA 1991, 88:334-852.
9. Levine A, Henderson BE, Groshen S, et al.: Immunization of HIV-1-infected individuals with inactivated HIV-1 immunogen: significance of HIV-1-specific cell-mediated immune response. VI International Conference on AIDS. San Francisco, June 1990 [abstract ThA337].
10. Montgomery DC: Design and Analysis ot Experiments, 2nd edn. New York: John Wiley and Sons; 1976:70-71.
11. Arthur LO, Bess JW, Sowder RC, et al.: Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992, 258:1935-1938.
12. Meerloo T, Sheikh MA, Bloem AC, et al.: Host cell membrane proteins on human immunodeficiency virus type 1 after in vitro infection of H9 cells and blood mononuclear cells. An immuno-electron microscopic study. J Gen Virol 1993, 74:129-135.
13. Gelderblom H, Reupke H, Winkel T, Kunze R, Pauli G: MHC-antigens: constituents of the envelopes of human and simian immunodeficiency viruses. Z Naturforsch 1987, 42c:1328-1334.
14. Cheingsong Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J, Weber J: Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ 1991, 302:236.
15. Pedersen C, Nielsen CM, Vestergaard BF, Gerstoft J, Krogsgaard K, Nielsen JO: Temporal relationship of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. BMJ (Clin Res Ed). 1987, 295:5679.
16. Kenealy W, Reed D, Cybulski R, et al.: Analysis of human serum antibodies to human immunodeficiency virus (HIV) using recombinant ENV and GAG antigens. AIDS Res Hum Retroviruses 1987, 3:95-105.
17. Trauger RJ, Giermakowska W, Ferre F, et al.: Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: correlation with virus burden. Immunology 1993, 78:14.
18. French MAH, Cameron PU, Grimsley G, Smyth L, Dawkins RL: Correction of human immunodeficiency virus associated depression of delayed-type hypersensitivity (DTH) after zidovudine therapy: DTH, CD4+ T cell numbers, and epidermal Langerhans cell density are independent variables. Clin Immunol Immunopathol 1990, 55:8696.
19. Trauger RJ, Ferre F, Daigle A, et al.: The effect of immunization with an inactivated gp120 depleted HIV-1 immunogen on HIV-1 immunity, viral DNA and CD4 percent. J Infect Dis 1994, 169:1256-1264.